• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.

作者信息

Satzger Imke, Ivanyi Philipp, Länger Florian, Kreipe Hans-Heinrich, Schaper-Gerhardt Katrin, Beutel Gernot, Cornberg Markus, Gutzmer Ralf

机构信息

Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Str. 1, 30625 Hannover, Germany.

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl Neuberg Str. 1, 30625 Hannover, Germany.

出版信息

Eur J Cancer. 2018 Apr;93:150-153. doi: 10.1016/j.ejca.2018.01.063. Epub 2018 Feb 19.

DOI:10.1016/j.ejca.2018.01.063
PMID:29472154
Abstract
摘要

相似文献

1
Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.纳武单抗联合伊匹单抗检查点抑制继发的治疗相关噬血细胞性淋巴组织细胞增生症
Eur J Cancer. 2018 Apr;93:150-153. doi: 10.1016/j.ejca.2018.01.063. Epub 2018 Feb 19.
2
Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.检查点抑制剂治疗所致继发性噬血细胞性淋巴组织细胞增生症
Eur J Cancer. 2019 Jul;115:84-87. doi: 10.1016/j.ejca.2019.04.026. Epub 2019 May 23.
3
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.黑色素瘤患者接受伊匹单抗+纳武单抗治疗后发生严重噬血细胞性淋巴组织细胞增生症。
J Immunother Cancer. 2018 Jul 16;6(1):73. doi: 10.1186/s40425-018-0384-0.
4
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.纳武单抗联合伊匹单抗或单独使用纳武单抗治疗晚期黑色素瘤相关的神经系统严重不良事件，包括一组脑炎病例
Oncologist. 2017 Jun;22(6):709-718. doi: 10.1634/theoncologist.2016-0487. Epub 2017 May 11.
5
Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy.纳武利尤单抗和伊匹单抗联合免疫治疗后噬血细胞性淋巴组织细胞增生症的黑素瘤患者的有效治疗。
Prague Med Rep. 2022;123(1):35-42. doi: 10.14712/23362936.2022.4.
6
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.纳武利尤单抗对比化疗用于 CTLA-4 治疗后进展的晚期黑色素瘤患者（CheckMate 037）：一项随机、对照、开放标签、III 期临床试验。
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
7
Dose-dependent toxicity of ipilimumab in metastatic melanoma.伊匹单抗在转移性黑色素瘤中的剂量依赖性毒性。
Eur J Cancer. 2018 May;95:104-108. doi: 10.1016/j.ejca.2018.01.088. Epub 2018 Feb 21.
8
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.新辅助与辅助伊匹单抗联合纳武利尤单抗治疗 III 期黑色素瘤的比较。
Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8.
9
Aseptic cystitis induced by nivolumab and ipilimumab combination for metastatic melanoma.纳武利尤单抗和伊匹单抗联合治疗转移性黑色素瘤引起的无菌性膀胱炎。
Melanoma Res. 2021 Oct 1;31(5):487-489. doi: 10.1097/CMR.0000000000000765.
10
Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.
Eur J Cancer. 2018 Apr;93:147-149. doi: 10.1016/j.ejca.2018.01.062. Epub 2018 Feb 12.

引用本文的文献

1
Tislelizumab-induced hemophagocytic lymphohistiocytosis in a patient with microsatellite instability-high colon cancer and coexisting systemic lupus erythematosus: a case report and literature review.替雷利珠单抗诱导的噬血细胞性淋巴组织细胞增生症在一名微卫星高度不稳定的结肠癌合并系统性红斑狼疮患者中的病例报告及文献复习
Front Oncol. 2025 Aug 6;15:1585133. doi: 10.3389/fonc.2025.1585133. eCollection 2025.
2
Promising Targeted Therapies for Hemophagocytic Lymphohistiocytosis: A Translational Perspective Based on Immunopathology.噬血细胞性淋巴组织细胞增生症的有前景的靶向治疗：基于免疫病理学的转化视角
Clin Rev Allergy Immunol. 2025 Jun 9;68(1):56. doi: 10.1007/s12016-025-09068-9.
3
Preoperative pembrolizumab‑induced hemophagocytic lymphohistiocytosis in a patient with breast cancer: A case report.
一名乳腺癌患者术前使用帕博利珠单抗诱发噬血细胞性淋巴组织细胞增生症：病例报告
Oncol Lett. 2025 Jan 9;29(3):136. doi: 10.3892/ol.2025.14882. eCollection 2025 Mar.
4
Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy.胶质母细胞瘤患者中与免疫治疗相关的继发性噬血细胞增多症：对细胞因子导向治疗的反应
Immunotherapy. 2025 Jan;17(1):11-17. doi: 10.1080/1750743X.2025.2451604. Epub 2025 Jan 15.
5
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.噬血细胞性淋巴组织细胞增生症：当前的治疗进展、新兴的靶向治疗和潜在机制。
J Hematol Oncol. 2024 Nov 7;17(1):106. doi: 10.1186/s13045-024-01621-x.
6
Fever of unknown origin associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的不明原因发热。
Front Immunol. 2024 Mar 12;15:1364128. doi: 10.3389/fimmu.2024.1364128. eCollection 2024.
7
Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.帕博利珠单抗联合贝伐珠单抗治疗宫颈癌后噬血细胞性淋巴组织细胞增生症：病例报告及系统评价。
BMC Geriatr. 2024 Jan 8;24(1):32. doi: 10.1186/s12877-023-04625-3.
8
Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor.采用免疫检查点抑制剂/酪氨酸激酶抑制剂治疗的肾小细胞癌。
IJU Case Rep. 2023 Aug 29;6(6):386-389. doi: 10.1002/iju5.12629. eCollection 2023 Nov.
9
Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.免疫检查点抑制剂相关噬血细胞性淋巴组织细胞增生症：一项药物警戒研究
J Clin Med. 2023 Mar 2;12(5):1985. doi: 10.3390/jcm12051985.
10
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.免疫检查点抑制剂的致命性系统性炎症综合征：病例报告和文献系统评价。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-005841.